- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
VIDEO: Gary Owens, MD, Talks About Trends in Rheumatoid Arthritis Management
Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies.
Gary Owens, MD, Gary Owens Associates, says that trends in rheumatoid arthritis management are coming from the new 2012 American College of Rheumatology guidelines that call for earlier and more aggressive treatment of new patients as well as patients who are not doing well on existing therapies. Dr Owens also discusses the drug costs associated with the treatment of rheumatoid arthritis. Health plans are looking to optimize value while managing cost.
This video was taken on November 8 at the NAMCP Fall Forum in Las Vegas, NV.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
